Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 203

Similar articles for PubMed (Select 20923265)

1.

MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.

El Sahly H.

Expert Rev Vaccines. 2010 Oct;9(10):1135-41. doi: 10.1586/erv.10.111. Review.

PMID:
20923265
2.

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.

Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A.

Pediatr Infect Dis J. 2009 Jul;28(7):563-71. doi: 10.1097/INF.0b013e31819d6394.

PMID:
19561422
3.

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.

Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, Nakura N, Lattanzi M.

Vaccine. 2012 Jul 13;30(33):5030-7. doi: 10.1016/j.vaccine.2012.03.053. Epub 2012 Apr 1.

PMID:
22472791
4.

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly.

De Donato S, Granoff D, Minutello M, Lecchi G, Faccini M, Agnello M, Senatore F, Verweij P, Fritzell B, Podda A.

Vaccine. 1999 Aug 6;17(23-24):3094-101.

PMID:
10462245
5.
6.

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.

Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M.

Vaccine. 2009 Oct 23;27(45):6291-5. doi: 10.1016/j.vaccine.2009.02.004.

PMID:
19840662
7.

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.

Black S, Della Cioppa G, Malfroot A, Nacci P, Nicolay U, Pellegrini M, Sokal E, Vertruyen A.

Vaccine. 2010 Oct 21;28(45):7331-6. doi: 10.1016/j.vaccine.2010.08.075. Epub 2010 Sep 15.

PMID:
20813217
8.

MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.

Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R; Family Medicine Group of Pianiga.

Vaccine. 2007 May 16;25(20):3955-61. Epub 2007 Mar 6.

PMID:
17383057
9.

Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.

Nassim C, Christensen S, Henry D, Holmes S, Hohenboken M, Kanesa-Thasan N.

Pediatr Infect Dis J. 2012 Apr;31(4):e59-65. doi: 10.1097/INF.0b013e31824b9545.

PMID:
22418661
10.
11.
12.

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.

Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, Noah DL, He F, Hill H.

J Infect Dis. 2008 Mar 1;197(5):667-75. doi: 10.1086/527489.

13.

Oil-in-water emulsion adjuvant with influenza vaccine in young children.

Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R.

N Engl J Med. 2011 Oct 13;365(15):1406-16. doi: 10.1056/NEJMoa1010331.

14.

Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.

Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, Clemens R.

Pediatrics. 2010 Oct;126(4):e762-70. doi: 10.1542/peds.2009-2628. Epub 2010 Sep 6.

15.

Vaccines for seasonal and pandemic influenza.

Nichol KL, Treanor JJ.

J Infect Dis. 2006 Nov 1;194 Suppl 2:S111-8.

16.

MF59 adjuvant: the best insurance against influenza strain diversity.

O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G.

Expert Rev Vaccines. 2011 Apr;10(4):447-62. doi: 10.1586/erv.11.23. Review.

PMID:
21506643
17.
18.
19.

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H.

Sci Transl Med. 2010 Jan 20;2(15):15ra5. doi: 10.1126/scitranslmed.3000624.

20.

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations.

Banzhoff A, Haertel S, Praus M.

Hum Vaccin. 2011 May;7(5):539-48. Epub 2011 May 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk